Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Expert Opinion on Therapeutic Targets|September 29, 2017
The potential of targeting Sin3B and its associated complexes for cancer therapyDavid J Cantor, Gregory DavidBlood|November 4, 2016
The chromatin-associated Sin3B protein is required for hematopoietic stem cell functions in miceDavid J Cantor, Gregory DavidClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2023
Targeting KRAS-Mutated NSCLC: Novel TKIs and BeyondDavid J Cantor, Charu AggarwalMolecular & Cellular Oncology|June 17, 2016
SIN3B, the SASP, and pancreatic cancerDavid J Cantor, Gregory DavidOncogene|September 30, 2014
Transcriptional repression of Sin3B by Bmi-1 prevents cellular senescence and is relieved by oncogene activationTeresa DiMauro, David J Cantor, Anthony J Bainor, et al.Cancer Research|August 16, 2017
Chromatin-Associated Protein SIN3B Prevents Prostate Cancer Progression by Inducing SenescenceAnthony J Bainor, Fang-Ming Deng, Yu Wang, et al.Cell Reports|January 4, 2019
Impaired Expression of Rearranged Immunoglobulin Genes and Premature p53 Activation Block B Cell Development in BMI1 Null MiceDavid J Cantor, Bryan King, Lili Blumenberg, et al.The Journal of Clinical Investigation|April 3, 2014
Senescence-associated SIN3B promotes inflammation and pancreatic cancer progressionMaïté Rielland, David J Cantor, Richard Graveline, et al.Clinical Lung Cancer|June 21, 2025
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLCDavid J Cantor, Halla Nimeiri, Leora Horn, et al.JTO Clinical and Research Reports|May 27, 2024
Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLCDavid J Cantor, Christiana Davis, Christine Ciunci, et al.Pageof 2